We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Summit Therapeutics Plc | LSE:SUMM | London | Ordinary Share | GB00BN40HZ01 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 20.50 | 18.00 | 23.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
06/1/2019 20:28 | Reckon we are in for a great week ahead here as buying momentum gathers! Will be happy with 32p close Friday | kirk 6 | |
05/1/2019 12:38 | Mmmmm now I wonder who may help the world with this? | barrieb | |
04/1/2019 19:14 | And as if to order....Now at $1.50 closing the premium. | waterloo01 | |
04/1/2019 16:31 | 21.5 above offer to buy 25k at close cold sell 250k on the bell with Peel2 at 20.27 this is going to take off at last it would seem | kirk 6 | |
04/1/2019 15:36 | Great news. This has massive potential here! 2019 will hopefully be a 10 Bagger | kirk 6 | |
04/1/2019 12:51 | Excellent all approved. New shares issued at $1.60. 20% premium to yesterdays close on Nasdaq. | waterloo01 | |
03/1/2019 21:17 | Ended up over 11% on the Nasdaq on substantial volume! Better day tomorrow it would seem | kirk 6 | |
03/1/2019 17:10 | Good to see it up (so far) 10% on Nasdaq, and on a very ugly market day. | waterloo01 | |
03/1/2019 17:07 | Up 10% on the Nasdaq!!!! | kirk 6 | |
03/1/2019 11:58 | Happy New Year hyper and Waterloo. Just back from WA. Lot of my family in NB over the NY. I take it you were up for the “loonie dook” hyper! | freedosh | |
03/1/2019 10:19 | Cheers Hyper. Hope life is treating you well. | waterloo01 | |
03/1/2019 09:13 | Wildbunch, to be honest I sold a load when they said the DMD trial was going from open label to some sort of hybrid where they didn't share full results. Didn't like the goal posts changing. However stopping the DMD investment instantly on disappointing results, was highly prudent. No point in flogging a zombie drug. As for upside, I'm not aware Dungan has a history of shafting holders. Quite the opposite from what I can tell. | waterloo01 | |
03/1/2019 09:00 | Best Stocks To Invest: FTD Companies, Inc. (FTD), Summit Therapeutics plc (SMMT) | football | |
03/1/2019 08:55 | Nice piece Waterloo-but how much is Robert W Duggan going to allow us to have of this upside? Any more money from him is not going to be non-dilutive is it. They are not fully funded through to end of phase 3, let alone to market. Agree shortish term upside is interesting for some. Personally I feel sore from way DMD was handled-pulling AGM forward from previous years and then announcement just a few weeks later. Don't believe that they did not know or at least had an inkling-so do not have sufficient trust to invest further. In to deep to get out. | wildbunch | |
02/1/2019 19:07 | Lagosboy, this is around 10% of my PF, so hardly eggs in one basket (my largest position today is a S&P short), but I do acknowledge I have a lot of time invested in SUMM but that does give me a fairly good view of the positives and negatives. Your correct the £2.50 share price (and at the time heading higher) was largely based on the now failed DMD drug. However what originally got me interested in SUMM was the C.diff drug (and more recently the other targets from Discuva Platform. I actually rate the C.diff drug very highly, it's an exquisite action in being so c.diff specific and is very likely to keep repeating the same results as it has ever since original lab tests. Given most of the c.diff cases are caused because of broad spectrum anti biotics used in a hospital setting (that and hygiene). It's also relatively cheap to produce and if they continue to show superiority to standard of care, it has a good chance to both get approval but also as 1st line treatment. If they price it right, it could quickly take the market. They certainly won't be taking it to market though. It will get bought once it's near or has approval, but it could easily be a $1bn drug. However as we all know, no one likes investing in antibiotics. Jim Oneal did a good study for the UK. He suggested making large pharma pay a levy if they didn't invest in the area. Ditto the FDA are looking at more pull initiatives. At some point, antibiotics will be back in 'fashion' and SUMM is well placed with an essentially funded trial and especially in these markets, no need now for further funds until much further down the road. | waterloo01 | |
02/1/2019 18:43 | Not got all my eggs in one basket hold 920k shares here and other big positions round some aim stocks Why are you so worried about objectivity are you worried this will rise? Why do you have the tendency to spread as much negativity as possible without looking at risk reward and potential upside ? Don't forget the price is 20p not £2 | kirk 6 | |
02/1/2019 17:06 | It was above $2 when it had a DMD drug and licensing partner signed up - that's gone now. Billion dollar blockbuster potential is pie the sky - hence no big pharma interest. Its not fully funded - its takes at least a $100m and more to take a drug to market and statistically there is still a very high probability that the C-Diff drug will fail to get necessary approvals. That is the reality and that is why pharma investing is highly specialised and should be done on wide portfolio basis. Too many people here with all their eggs in one basket hence the loss of objectivity in the claims. | lagosboy | |
02/1/2019 16:33 | Think these have been overdone from above £2 and now fully funded for a really exciting 2019, along with talking my book | kirk 6 | |
02/1/2019 16:04 | KIRK 6 WHY? | wildbunch | |
02/1/2019 14:04 | Really optimistic this will be near £1 by end of Q1 early Q2 | kirk 6 | |
02/1/2019 12:42 | Anyone building a stake is good news !Roll on massive upside here in 2019 | kirk 6 | |
02/1/2019 12:41 | Assuming no more dilution (a big, big if)then each £1bn of market cap = £6 share price. That is £3 for Mr Robert W Duggan and £3 for the rest of us. If drug works well and some of rest of pipeline works then market cap will be well north of £1bn. BUT lagosboy has a point- why would Duggan want to share with the rest of us if he can avoid that? The one thing in our favour is the 2.5m (approx) options @ 29.5p owned by our CEO. But one can imagine a scenario where the company is taken private with the CEO still employed with a new arrangement which leaves him no worse off. I can see Waterloo's point about current valuation being low on short term basis but am deeply sceptical about us being able to enjoy a potential a long term 30+ bagger. I am long term holder at average of around £1.5 so will continue for the ride! | wildbunch | |
02/1/2019 12:36 | I'm not saying it was fair value (which should be higher) but given share price was around 18/19p a large investment at 25p is, I believe a premium. Any further investments will be for the benefit of all holders, and him the most as the largest holder. | waterloo01 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions